| Project/Area Number |
18K08755
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55030:Cardiovascular surgery-related
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
海野 直樹 浜松医科大学, 医学部, 特任研究員 (20291958)
佐野 真規 浜松医科大学, 医学部附属病院, 助教 (40733514)
斉藤 貴明 浜松医科大学, 医学部附属病院, 診療助教 (80793364)
片橋 一人 浜松医科大学, 医学部附属病院, 診療助教 (60839091)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 血管外科 / 腹部大動脈瘤 / MRI / ずり応力 / リンパ管新生 / 血管新生 / 蛍光造影 / 抗血小板薬 / リンパ管 / PET / 刷り応力 / 脈管申請 |
|---|
| Outline of Final Research Achievements |
Histological examination revealed chronic inflammation and angiogenesis / lymphangiogenesis in the intima and tunica media of the aortic aneurysm. Inflammatory cells, lymphangiogenesis, and lymphatic stasis were histologically observed in sites where lymphatic luminescence was remarkably evoked by ICG fluorescence imaging examination of the aortic wall. It was suggested that chronic inflammation and lymphangiogenesis are related to development and increase of aortic aneurysm. The distribution of wall shear stress was not related to lymphangiogenesis or chronic inflammation. The new antiplatelet drug (K-134) was effective in suppressing the expansion and preventing rupture of the aneurysm in a rat aneurysm model.
|
| Academic Significance and Societal Importance of the Research Achievements |
動脈瘤の発生や破裂にメカニズムとして、瘤壁の血流低下、低酸素状態、慢性炎症の持続が負のサイクルとなって影響していることが証明された。血流力学的影響は明らかにできなかったが、まだ調査の余地がある。血流改善と抗炎症作用を有する抗血小板薬（K-134）がラット動脈瘤モデルでは、瘤径拡大抑制や破裂予防効果があることを証明できた。今後、ヒトの動脈瘤でも同様の効果が期待でき、将来は動脈瘤を手術することなく治療できるようになる希望が得られた。
|
